TCGA-DQ-7592-01A-11R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.560
- INTERFERON_GAMMA_RESPONSE+0.400
- TGF_BETA_SIGNALING+0.400
- MYOGENESIS+0.370
- WNT_BETA_CATENIN_SIGNALING+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- UV_RESPONSE_DN+0.280
- IL6_JAK_STAT3_SIGNALING+0.260
- ANGIOGENESIS+0.250
- MITOTIC_SPINDLE+0.240
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- FATTY_ACID_METABOLISM-0.310
- PEROXISOME-0.220
- BILE_ACID_METABOLISM-0.150
- ADIPOGENESIS-0.140
- E2F_TARGETS-0.140
- XENOBIOTIC_METABOLISM-0.140
- MYC_TARGETS_V1-0.130
- DNA_REPAIR-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-6545-01A-11R-1820-07 | — | cohortSQ1 | 0.820 |
| 2 | TCGA-85-8287-01A-11R-2296-07 | — | cohortSQ1 | 0.812 |
| 3 | TCGA-CV-6959-01A-11R-1915-07 | — | — | 0.805 |
| 4 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.787 |
| 5 | 20050166.TNBC | — | D | 0.778 |
| 6 | TCGA-CN-5370-01A-01R-2016-07 | — | — | 0.777 |
| 7 | TCGA-85-8582-01A-21R-2403-07 | — | cohortSQ1 | 0.777 |
| 8 | TCGA-CN-6996-01A-11R-1915-07 | — | — | 0.770 |
| 9 | MNG248 | — | — | 0.767 |
| 10 | TCGA-DK-A3IU-01A-11R-A20F-07 | — | — | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |